LAMPRENE

This brand name is authorized in Estonia, France, Malta, South Africa.

Active ingredients

The drug LAMPRENE contains one active pharmaceutical ingredient (API):

1	Chlofazimine UNII D959AE5USF - CLOFAZIMINE
	Clofazimine is an antimycobacterial drug. Clofazimine exerts a slow bactericidal effect on Mycobacterium leprae (Hansen’s bacillus). Clofazimine inhibits mycobacterial growth and binds preferentially to mycobacterial DNA.
	Read more about Chlofazimine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LAMPRENE Soft gelatin capsule	MPI, Generic	Health Products Regulatory Authority (ZA)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J04BA01	Clofazimine	J Antiinfectives for systemic use → J04 Antimycobacterials → J04B Drugs for treatment of lepra → J04BA Drugs for treatment of lepra
Discover more medicines within J04BA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1738357
FR	Base de données publique des médicaments	62768220, 67132888
MT	Medicines Authority	AA565/45101
ZA	Health Products Regulatory Authority	53/20.2.4/0472, B/20.2.4/108